Supplement and pharmaceutical evidence, held to the same standard, on the same page.
Dr. Johnston looks at studies linking obesity to cancer and examines whether GLP-1 medications are associated with lower cancer risk, noting that the evidence is observational.
Dr. Johnston ranks the ten supplements and repurposed generic drugs he would put on his own shortlist, weighing human trials first, then animal and laboratory research.
Dr. Johnston looks at what studies in animals and people report about gut bacteria, probiotics and the response to cancer immunotherapy.
Large analyses link statins to lower cancer mortality, but the data are observational and a bias-corrected analysis found no difference. Here is what they show.
Lab studies explore how methylene blue interacts with light and cancer cell energy use. Human evidence is thin, and the drug-interaction risks are serious.
A meta-analysis of small randomized trials linked melatonin to better tumor response and one-year survival, but later blinded trials did not confirm the benefit.
The ALASCCA trial found low-dose aspirin cut colorectal cancer recurrence in tumors with PI3K pathway changes. Here is what it shows and the bleeding risks.
PSK, a Turkey Tail extract used in Japan, was tested in randomized cancer trials. The survival signal is modest and low certainty, and tea is not the extract.
Dr. Johnston asks whether MTHFR variants matter more under stress such as COVID-19, and why he turned to L-methylfolate.
Methylene blue is approved for one blood condition and studied in cancer cells and mice. No human trial shows it treats cancer, and it interacts with common medicines.
Mebendazole, a long-used deworming drug, shows anticancer activity in lab models. Human data are limited and early, and liver and marrow effects matter.
Ivermectin has shown effects on cancer cells in the lab, but at levels far above what people can reach. Human evidence is very limited, and safety matters.
Elemene is a compound from Curcuma plants, studied in cancer cells and used in China as an add-on. The trials are low quality, so benefit remains unproven.